An additional activation of the HGF/MET pathway—that may function as a compensatory route—has been reported in some other tumors [19, 38], but the first description of MET overexpression in HNSCC patients [39] was published only recently. The gene discussed is HGF; the disease is head and neck squamous cell carcinoma.